These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1313691)

  • 21. 4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.
    Schütte J; Niederle N; Grunenberg B; Krischke W; Seeber S; Schmidt CG
    J Cancer Res Clin Oncol; 1984; 107(1):38-41. PubMed ID: 6583205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
    Miller DK; Munshi N; Loesch D; Einhorn LE; Sledge GW
    Cancer; 2000 Jan; 88(2):375-80. PubMed ID: 10640971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
    Yang CH; Chen MC; Cheng AL; Hsu CH; Yeh KH; Yu YC; Whang-Peng J; Yang PC
    Oncology; 2005; 68(4-6):350-5. PubMed ID: 16020962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
    Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
    Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
    Nishio M; Ohata M; Kobayashi H; Suruda T; Uetani K; Funasako M; Nishio K; Sasaki Y; Saijo N
    Jpn J Clin Oncol; 1993 Oct; 23(5):284-90. PubMed ID: 8230753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG).
    Eckhardt S; Kolaric K; Vukas D; Kánitz E; Schoket Z; Jassem J; Vuletic L; Jelic S; Mechl Z; Koza I
    Med Oncol Tumor Pharmacother; 1990; 7(1):19-23. PubMed ID: 2160033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.
    Vici P; Ferraironi A; Di Lauro L; Carpano S; Conti F; Belli F; Paoletti G; Maini CL; Lopez M
    Clin Ter; 1998; 149(921):15-20. PubMed ID: 9621483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.
    Akerley W
    Chest; 2000 Apr; 117(4 Suppl 1):152S-155S. PubMed ID: 10777471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.
    Payne M; Ellis P; Dunlop D; Ranson M; Danson S; Schacter L; Talbot D
    J Thorac Oncol; 2006 Nov; 1(9):984-90. PubMed ID: 17409983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A phase II study of epirubicin in advanced lung cancer].
    Furuse K; Fukuoka M; Yamamoto M; Kawahara M; Tsuruta M; Kodama N; Arai R; Hayashi S; Kiyota M; Kubota K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2835-40. PubMed ID: 3019252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study.
    Carabante-Ocón F; Cobo-Dols M; Benavides-Orgaz M; Gil-Calle S; Alés-Díaz I; Bretón-García JJ; Villar-Chamorro E; Montesa-Pino A; Alcalde-García J; Gutiérrez-Calderón V
    Clin Lung Cancer; 2005 Sep; 7(2):121-6. PubMed ID: 16179099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
    Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
    Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.